N Pagnussat1, A S Almeida1, D M Marques1, F Nunes1, G C Chenet1, P H S Botton1, S Mioranzza1, C M Loss1, R A Cunha2,3, L O Porciúncula1. 1. Laboratório de Estudos sobre o Sistema Purinérgico, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. 2. Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal. 3. Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Abstract
BACKGROUND AND PURPOSE: Caffeine (a non-selective adenosine receptor antagonist) prevents memory deficits in aging and Alzheimer's disease, an effect mimicked by adenosine A2 A receptor, but not A1 receptor, antagonists. Hence, we investigated the effects of adenosine receptor agonists and antagonists on memory performance and scopolamine-induced memory impairment in mice. EXPERIMENTAL APPROACH: We determined whether A2 A receptors are necessary for the emergence of memory impairments induced by scopolamine and whether A2 A receptor activation triggers memory deficits in naïve mice, using three tests to assess short-term memory, namely the object recognition task, inhibitory avoidance and modified Y-maze. KEY RESULTS: Scopolamine (1.0 mg·kg(-1) , i.p.) impaired short-term memory performance in all three tests and this scopolamine-induced amnesia was prevented by the A2 A receptor antagonist (SCH 58261, 0.1-1.0 mg·kg(-1) , i.p.) and by the A1 receptor antagonist (DPCPX, 0.2-5.0 mg·kg(-1) , i.p.), except in the modified Y-maze where only SCH58261 was effective. Both antagonists were devoid of effects on memory or locomotion in naïve rats. Notably, the activation of A2 A receptors with CGS 21680 (0.1-0.5 mg·kg(-1) , i.p.) before the training session was sufficient to trigger memory impairment in the three tests in naïve mice, and this effect was prevented by SCH 58261 (1.0 mg·kg(-1) , i.p.). Furthermore, i.c.v. administration of CGS 21680 (50 nmol) also impaired recognition memory in the object recognition task. CONCLUSIONS AND IMPLICATIONS: These results show that A2 A receptors are necessary and sufficient to trigger memory impairment and further suggest that A1 receptors might also be selectively engaged to control the cholinergic-driven memory impairment.
BACKGROUND AND PURPOSE:Caffeine (a non-selective adenosine receptor antagonist) prevents memory deficits in aging and Alzheimer's disease, an effect mimicked by adenosine A2 A receptor, but not A1 receptor, antagonists. Hence, we investigated the effects of adenosine receptor agonists and antagonists on memory performance and scopolamine-induced memory impairment in mice. EXPERIMENTAL APPROACH: We determined whether A2 A receptors are necessary for the emergence of memory impairments induced by scopolamine and whether A2 A receptor activation triggers memory deficits in naïve mice, using three tests to assess short-term memory, namely the object recognition task, inhibitory avoidance and modified Y-maze. KEY RESULTS:Scopolamine (1.0 mg·kg(-1) , i.p.) impaired short-term memory performance in all three tests and this scopolamine-induced amnesia was prevented by the A2 A receptor antagonist (SCH 58261, 0.1-1.0 mg·kg(-1) , i.p.) and by the A1 receptor antagonist (DPCPX, 0.2-5.0 mg·kg(-1) , i.p.), except in the modified Y-maze where only SCH58261 was effective. Both antagonists were devoid of effects on memory or locomotion in naïve rats. Notably, the activation of A2 A receptors with CGS 21680 (0.1-0.5 mg·kg(-1) , i.p.) before the training session was sufficient to trigger memory impairment in the three tests in naïve mice, and this effect was prevented by SCH 58261 (1.0 mg·kg(-1) , i.p.). Furthermore, i.c.v. administration of CGS 21680 (50 nmol) also impaired recognition memory in the object recognition task. CONCLUSIONS AND IMPLICATIONS: These results show that A2 A receptors are necessary and sufficient to trigger memory impairment and further suggest that A1 receptors might also be selectively engaged to control the cholinergic-driven memory impairment.
Authors: E Clea Warburton; Timothy Koder; Kwangwook Cho; Peter V Massey; Gail Duguid; Gareth R I Barker; John P Aggleton; Zafar I Bashir; Malcolm W Brown Journal: Neuron Date: 2003-06-19 Impact factor: 17.173
Authors: Grace S Pereira; Tadeu Mello e Souza; Elsa R C Vinadé; Humberto Choi; Cristina Rodrigues; Ana M O Battastini; Iván Izquierdo; João J F Sarkis; Carla D Bonan Journal: Eur J Pharmacol Date: 2002-02-22 Impact factor: 4.432
Authors: Lydia Giménez-Llort; Alberto Fernández-Teruel; Rosa Maria Escorihuela; Bertil B Fredholm; Adolf Tobeña; Milos Pekny; Björn Johansson Journal: Eur J Neurosci Date: 2002-08 Impact factor: 3.386
Authors: Ana Patrícia Simões; Nuno J Machado; Nélio Gonçalves; Manuella P Kaster; Ana T Simões; Ana Nunes; Luís Pereira de Almeida; Ki Ann Goosens; Daniel Rial; Rodrigo A Cunha Journal: Neuropsychopharmacology Date: 2016-06-17 Impact factor: 7.853
Authors: Nuno J Machado; Ana Patrícia Simões; Henrique B Silva; Ana Paula Ardais; Manuella P Kaster; Pedro Garção; Diana I Rodrigues; Daniela Pochmann; Ana Isabel Santos; Inês M Araújo; Lisiane O Porciúncula; Ângelo R Tomé; Attila Köfalvi; Jean-Marie Vaugeois; Paula Agostinho; Malika El Yacoubi; Rodrigo A Cunha; Catarina A Gomes Journal: Mol Neurobiol Date: 2016-02-09 Impact factor: 5.590
Authors: Anthony Zulli; Renee M Smith; Peter Kubatka; Jan Novak; Yoshio Uehara; Hayley Loftus; Tawar Qaradakhi; Miroslav Pohanka; Nazarii Kobyliak; Angela Zagatina; Jan Klimas; Alan Hayes; Giampiero La Rocca; Miroslav Soucek; Peter Kruzliak Journal: Eur J Nutr Date: 2016-03-01 Impact factor: 5.614
Authors: Fabio C Tescarollo; Diogo M Rombo; Lindsay K DeLiberto; Denise E Fedele; Enmar Alharfoush; Ângelo R Tomé; Rodrigo A Cunha; Ana M Sebastião; Detlev Boison Journal: J Caffeine Adenosine Res Date: 2020-06-04